BeOne Medicines Ltd (HK:6160)
:6160
6160 Stock Chart & Stats
HK$182.30
HK$5.50(5.26%)
At close: 4:00 PM EST
HK$182.30
HK$5.50(5.26%)
Day’s Range― - ―
52-Week RangeHK$115.80 - HK$229.40
Previous CloseN/A
Volume1.62M
Average Volume (3M)5.08M
Market Cap
HK$277.46B
Enterprise ValueHK$32.46B
Total Cash (Recent Filing)HK$4.59B
Total Debt (Recent Filing)HK$1.09B
Price to Earnings (P/E)124.8
Beta1.02
Next Earnings
Apr 30, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding1,426,363,900
10 Day Avg. Volume3,608,600
30 Day Avg. Volume5,076,742
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$244.26Price Target Upside33.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)3.66
Revenue Forecast (FY)HK$50.12B
Bulls Say, Bears Say
Bulls Say
Return To ProfitabilityBeiGene/BeOne reported a clear profitability inflection in 2025, with revenue growth and a positive ~5.4% net margin. A sustained shift from loss to profit materially reduces near-term financing needs, proving commercial traction of core products and improving long-term funding flexibility for R&D and expansion.
Strong Cash GenerationMaterial positive operating and free cash flow in 2025 indicates earnings are converting into real cash, supporting organic investment, manufacturing expansion and milestone-funded partnerships. Durable cash generation improves resilience versus prior burn and reduces reliance on dilutive financing if maintained.
High Gross MarginsAn ~85% gross margin signals strong pricing power and favorable product economics typical of established oncology drugs. High gross margins provide structural capacity to fund SG&A and R&D, supporting sustained investment in commercial expansion and pipeline development without proportionate revenue growth.
Bears Say
Short Profit Track RecordProfitability in a single year after multiple years of losses raises durability concerns. One-year inflection may reflect timing of launches or milestones rather than stable earnings power; future quarters could revert, complicating planning, capital allocation and investor confidence over the medium term.
Inconsistent Historical Cash FlowA history of multi-year negative cash flow increases execution and refinancing risk if revenue growth slows. Even with 2025 cash generation, the prior pattern shows sensitivity to clinical/regulatory outcomes and launch execution; inconsistent cash makes long-term R&D pacing and manufacturing scale-up riskier.
Pipeline & Regulatory Concentration RiskThe business is heavily dependent on oncology approvals and trial outcomes; trial terminations or regulatory setbacks can materially curtail future sales and milestones. Even positive designations (eg, orphan status) coexist with high binary risk, concentrating upside and downside on clinical progress.
BeOne Medicines Ltd News
6160 FAQ
What was BeOne Medicines Ltd’s price range in the past 12 months?
BeOne Medicines Ltd lowest stock price was HK$115.80 and its highest was HK$229.40 in the past 12 months.
What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is HK$277.46B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s upcoming earnings report date is Apr 30, 2026 which is in 22 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on Mar 25, 2026. The company reported HK$0.361 earnings per share for the quarter, missing the consensus estimate of HK$0.746 by -HK$0.385.
Is BeOne Medicines Ltd overvalued?
According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 0.61.
How many shares outstanding does BeOne Medicines Ltd have?
BeOne Medicines Ltd has 1,426,363,900 shares outstanding.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of HK$0.361 in its last earnings report, missing expectations of HK$0.746. Following the earnings report the stock price went up 0.42%.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in HK:6160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$244.26 (33.99% Upside)
HK$244.26 (33.99% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
7.28%
Trailing 12-Months
Asset Growth
39.22%
Trailing 12-Months
Company Description
BeOne Medicines Ltd
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
6160 Stock 12 Month Forecast
Average Price Target
HK$244.26
▲(33.99% Upside)
Technical Analysis
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
WuXi AppTec Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
―
Options Prices
Currently, No data available
---